CompletedPHASE1, PHASE2NCT02706886
Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1
Studying Primary hyperoxaluria type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alnylam Pharmaceuticals
- Principal Investigator
- Tracy McGregor, MD, MSCIAlnylam Pharmaceuticals
- Intervention
- Lumasiran(drug)
- Enrollment
- 52 enrolled
- Eligibility
- 6-64 years · All sexes
- Timeline
- 2016 – 2019
Study locations (9)
- Clinical Trial Site, Bordeaux, France
- Clinical Trial Site, Lyon, France
- Clinical Trial Site, Paris, France
- Clinical Trial Site, Bonn, Germany
- Clinical Trial Site, Haifa, Israel
- Clinical Trial Site, Jerusalem, Israel
- Clinical Trial Site, Amsterdam, Netherlands
- Clinical Trial Site, Birmingham, United Kingdom
- Clinical Trial Site, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02706886 on ClinicalTrials.govOther trials for Primary hyperoxaluria type 1
Additional recruiting or active studies for the same condition.